Please provide your email address to receive an email when new articles are posted on . The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG IgG4-RD can occur in multiple organs and lead to fibrosis and ...

(MENAFN- GetNews) "IgG4-Related Disease Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Uplizna met all primary and secondary endpoints for ...

Inebilizumab-cdon, a monoclonal antibody that depletes B cells, reduces the risk for flares without showing any new safety signals in patients with immunoglobulin G4-related disease (IgG4-RD) who have ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD). An international, ...

Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval for Uplizna, now approved as a treatment for immunoglobulin G4-related ...

Autoimmune pancreatitis often mimics pancreatic cancer, and for clinicians, distinguishing Type 1 (IgG4) from Type 2 (IBD) is ...

Thalidomide demonstrated superior efficacy in preventing the relapse of immunoglobulin G4–related disease (IgG4-RD) during a 12-month follow-up period in a placebo-controlled trial. The treatment ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing ...